In an era where drug-resistant bacteria threaten global health, a new class of antibiotics is emerging as a beacon of hope.Kinvard Bio, a pioneering startup from Harvard University, is at the forefront of this antibacterial innovation, actively developing compounds aimed at combating the longstanding challenges posed by antibiotic resistance.